Adding to the confusion in more than just the name
Jacob George
Clin Mol Hepatol. 2023;29(4):973-976.   Published online 2023 Sep 18     DOI: https://doi.org/10.3350/cmh.2023.0367
Citations to this article as recorded by Crossref logo
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
Diabetes & Metabolism.2024; 50(1): 101506.     CrossRef
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
European Journal of Gastroenterology & Hepatology.2024; 36(4): 430.     CrossRef
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice
Paul N Brennan, Oliver D Tavabie, Wenhao Li, Thomas Marjot, Lynsey Corless, Jonathan A Fallowfield, Helen Jarvis, Dina Mansour, Stuart McPherson, William Rosenberg, Karen Rockell, Jeremy Tomlinson, Andrew Yeoman, Emmanuel A Tsochatzis, John F Dillon, Will
The Lancet Gastroenterology & Hepatology.2024; 9(6): 577.     CrossRef
Does an Aspirin a Day Take the MASLD Away?
Amedeo Lonardo, Ming-Hua Zheng
Advances in Therapy.2024; 41(7): 2559.     CrossRef
Neuroimmune modulation in liver pathophysiology
Ju Zou, Jie Li, Xiaoxu Wang, Daolin Tang, Ruochan Chen
Journal of Neuroinflammation.2024;[Epub]     CrossRef
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
Clinical and Molecular Hepatology.2023; 30(1): 118.     CrossRef